JPMorgan lowered the firm’s price target on Vera Therapeutics (VERA) to $96 from $99 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics: Reinforced Buy on Atacicept’s Leading IgAN Profile, Robust Cash Runway, and Expanded Peak Sales Potential
- Vera Therapeutics Announces Departure of Chief Legal Officer
- Vera Therapeutics director buys $250K in common stock
- Vera Therapeutics price target raised to $33 from $23 at Wedbush
- Vera Therapeutics Completes Successful Stock Offering